New Drug "Cocktail" Shows Dramatic Improvements for AMD Treatment
A new anti-PDGF drug improves vision in AMD patients when combined with anti-VEGF therapy.
A press release from Ophthotech Corporation announced positive results from a clinical trial of their drug Fovista. This drug is directed against a platelet-derived growth factor (PDGF-B), which regulates cells associated with newly formed small blood vessels.
The phase 2 trial of 449 patients with wet AMD showed that Fovista in combination with Lucentis resulted in a gain of 10.6 letters of vision on the standardized chart at 24 weeks, compared to those taking only Lucentis and gaining only 6.5 letters.
“This is a truly remarkable finding for patients with wet AMD. To achieve a 62% relative visual benefit over anti-Vegf monotherapy is extraordinary,” said Carmen A. Puliafito, Md.D., retina specialist.
Ophthotech is planning a phase 3 trial to bring anti-PDGF therapy to patients with wet AMD as soon as possible.
If you found this article interesting, you can get updates in your email inbox any time similar articles are posted. The subscription options you will be presented with are based on your interest in this article. Just click here to sign up for a free membership and get started!